Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 92Other hematologic neoplasm 81Myeloid 31Plasma cell 18Classical hematology 12Dermatologic 6Genitourinary 5Sarcoma 4CNS 4Gynecologic 3Breast 2Other neoplasm 1Gastrointestinal 1

Conditions

Unrecognized Condition: Mature B or T-cell Neoplasm 1

Interventions

Surveys and Questionnaires 9Cyclophosphamide 9Whole-Body Irradiation 7Biopsy 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Educational Status 6Early Intervention, Educational 6Busulfan 6Methotrexate 5Methods 5Immunohistochemistry 5Epoetin Alfa 5Tacrolimus 4Mycophenolic Acid 4Interviews as Topic 4Gene Expression Profiling 4Decitabine 4Cyclosporine 4Celecoxib 4Antilymphocyte Serum 4fludarabine 3Sirolimus 3Radiotherapy 3Paclitaxel 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Imiquimod 3Fentanyl 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Alemtuzumab × Other neoplasm × Clear all
NCT02701517 2017-12-29

Cyclosporine Plus Methotrexate or Alemtuzumab

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Terminated
72 enrolled
LymphoidOther neoplasm

Unrecognized Condition: Mature B or T-cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡